Richard Spruyt

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

H. Kantarjian, J. Cortes, K. Yee, 2013, The Lancet. Oncology.